Abstract
The accumulation of amyloid β peptide (Aβ) is believed to be an early and critical event leading to synapse and neuronal cell loss in Alzheimers Disease (AD). Aβ itself is toxic to neurons in vitro and the load of Aβ in vivo causes the loss of synapses and neurons in brain in animal models. Therefore, there has been considerable interest in elucidating the mechanism(s) of Aβ neurotoxicity. Here, we review the molecular signaling pathways involved in Aβ-induced cell death, including signaling through the neuronal nicotinic receptor and the Aβ-triggered generation of reactive oxygen species (ROS) leading to the activation of the c-jun N-terminal kinase (JNK), and the ensuing phosphorylation of p66Shc and inactivation of the Forkhead transcription factors. This focused review not only provides a better understanding of the signaling mechanisms involved in Aβ-induced cell death, but also underscores the potential of JNK, p66Shc, Forkhead proteins, p25/cdk5, and neuronal nicotinic receptor, as therapeutic targets for AD.
Keywords: JNK, p66Shc, Forkhead proteins, cdk5, apoptosis, phosphorylation, reactive oxygen species, neuronal nicotinic receptor
CNS & Neurological Disorders - Drug Targets
Title: Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease
Volume: 5 Issue: 3
Author(s): Wanli W. Smith, Myriam Gorospe and John W. Kusiak
Affiliation:
Keywords: JNK, p66Shc, Forkhead proteins, cdk5, apoptosis, phosphorylation, reactive oxygen species, neuronal nicotinic receptor
Abstract: The accumulation of amyloid β peptide (Aβ) is believed to be an early and critical event leading to synapse and neuronal cell loss in Alzheimers Disease (AD). Aβ itself is toxic to neurons in vitro and the load of Aβ in vivo causes the loss of synapses and neurons in brain in animal models. Therefore, there has been considerable interest in elucidating the mechanism(s) of Aβ neurotoxicity. Here, we review the molecular signaling pathways involved in Aβ-induced cell death, including signaling through the neuronal nicotinic receptor and the Aβ-triggered generation of reactive oxygen species (ROS) leading to the activation of the c-jun N-terminal kinase (JNK), and the ensuing phosphorylation of p66Shc and inactivation of the Forkhead transcription factors. This focused review not only provides a better understanding of the signaling mechanisms involved in Aβ-induced cell death, but also underscores the potential of JNK, p66Shc, Forkhead proteins, p25/cdk5, and neuronal nicotinic receptor, as therapeutic targets for AD.
Export Options
About this article
Cite this article as:
Smith W. Wanli, Gorospe Myriam and Kusiak W. John, Signaling Mechanisms Underlying Aβ Toxicity: Potential Therapeutic Targets for Alzheimers Disease, CNS & Neurological Disorders - Drug Targets 2006; 5 (3) . https://dx.doi.org/10.2174/187152706784111515
DOI https://dx.doi.org/10.2174/187152706784111515 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Stem Cell-Like Brain Cancer Cells
Current Cancer Therapy Reviews Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Biomarkers
Current Pharmaceutical Design Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Protein & Peptide Letters Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Pharmacological Approaches of Neurofibrillary Degeneration
Current Alzheimer Research Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Current Medicinal Chemistry Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research MicroRNAs in the Pathobiology of Multiple Myeloma
Current Cancer Drug Targets Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Tumor Markers: The Potential of “Omics” Approach
Current Molecular Medicine The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets